Quantum-Si incorporated
NASDAQ:QSIBiotechnology
+$0.05 today
- Market cap
- $213.79M
- Beta
- 3.17
- P/E (TTM)
- -2.1
- EPS (TTM)
- -$0.48
Volume 10.47M
Average 5.64M
QSI Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Quantum-Si incorporatedNASDAQ: QSI
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents falls 2.9% from a year ago
Cash & equivalents stood at $36.2M at the end of Q1 FY2026, down 2.9% from a year earlier and up 67.3% from the prior quarter. Over 3 fiscal years it compounded at -36.5% a year.
Context
- Cash & equivalents amounted to 17.0% of total assets at the end of Q1 FY2026, up 3.2 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -2.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 21.64M USD
- Year-over-year change
- -56.1%
- 4-year CAGR
- -11.8%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 21.64M | -56.1% |
| FY2024 | 2024-12-31 | 49.24M | -63.2% |
| FY2023 | 2023-12-31 | 133.86M | +58.8% |
| FY2022 | 2022-12-31 | 84.32M | +135.6% |
| FY2021 | 2021-12-31 | 35.79M | — |
Cash & Equivalents vs competitors
How QSI compares with its peers on the latest reported figures
- QSI's Mar 2026 cash & equivalents of $36.2M is the 10th highest of the 11 companies compared; the peer median is $153.07M.
- Its year-over-year change of -2.9% is the 10th highest of 11, against a peer median of +60.9%.
- Cash & equivalents amounts to 17.0% of total assets for QSI, versus a peer median of 64.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $320.68M | +2154.3% | +126.9% | 81.5% |
| Mar 2026 | $297.74M | +41.4% | -27.2% | 70.4% | |
| Mar 2026 | $231.01M | +18.6% | -7.1% | 79.2% | |
| Mar 2026 | $229.2M | +1668.2% | -2.5% | 86.0% | |
| Mar 2026 | $175.21M | +80.4% | +5.0% | 66.6% | |
| Mar 2026 | $130.93M | +36.7% | -35.2% | 24.8% | |
| Mar 2026 | $97.6M | +98.8% | -26.7% | 29.1% | |
| Mar 2026 | $84.79M | +121.8% | -21.2% | 61.6% | |
| Mar 2026 | $49.61M | -0.4% | -18.0% | 17.4% | |
| Mar 2026 | $36.2M | -2.9% | -36.5% | 17.0% | |
ENGNenGene Holdings Inc. | Apr 2026 | $29.83M | -48.2% | +442.5% | 9.7% |
| Peer median (excluding QSI) | $153.07M | +60.9% | -12.6% | 64.1% | |
Competitors are the stored peer set for QSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 35.79M | 84.32M | 133.86M | 49.24M | 21.64M |
| Short-term Investments | 435.52M | 266.99M | 123.88M | 160.36M | 141.27M |
| Net Receivables | 0 | 0 | 368K | 1.33M | 561K |
| Inventory | 0 | 0 | 3.95M | 4.07M | 3.2M |
| Other Current Assets | 5M | 6.87M | 4.26M | 3.01M | 9.19M |
| Total Current Assets | 477.17M | 358.18M | 266.31M | 218.01M | 175.86M |
| Property, Plant & Equipment (Net) | 15.88M | 32.61M | 30.71M | 29.05M | 16.66M |
| Goodwill | 9.48M | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 532K | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 52.86M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 690K | 697K | 695K | 808K | 234K |
| Total Non-current Assets | 26.05M | 33.3M | 31.94M | 29.86M | 69.75M |
| Total Assets | 503.23M | 391.49M | 298.25M | 247.87M | 245.61M |
| Account Payables | 3.39M | 3.9M | 1.77M | 1.93M | 1.62M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 1.34M | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 3.49M |
| Other Current Liabilities | 2.7M | 88K | 194K | 514K | (1.74M) |
| Total Current Liabilities | 11.53M | 15.71M | 11.61M | 18.19M | 23.03M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 7.45M | 996K | 1.29M | 5.01M | 34K |
| Total Non-current Liabilities | 14.66M | 17.07M | 15.02M | 14.26M | 2.36M |
| Total Liabilities | 26.19M | 32.78M | 26.63M | 32.45M | 25.38M |
| Common Stock | 14K | 14K | 14K | 18K | 22K |
| Retained Earnings | (267.23M) | (399.67M) | (495.63M) | (596.64M) | (697.98M) |
| Accumulated OCI | 0 | 0 | 0 | 45K | (6K) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 477.03M | 358.71M | 271.62M | 215.42M | 220.23M |
| Total Debt | 8.08M | 17.45M | 15.3M | 12.95M | 4.17M |
| Net Debt | (27.71M) | (66.87M) | (118.56M) | (36.29M) | (17.47M) |
Quantum-Si incorporated
NASDAQ:QSI
Intrinsic Alpha fair value
Locked
Current Price
$1.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.